Hantavirus Breakthroughs Face Funding Hurdles Despite Cruise Outbreak

Top Summary

• What happened: Researchers have developed promising hantavirus vaccines and treatments, but struggle to secure funding for clinical trials.
• Why it matters: Hantaviruses are highly lethal, and climate change could increase contact between humans and rodent hosts.
• What changes for people: Successful therapies like tocilizumab could save lives, but their availability remains severely limited.
• Who is affected: Local populations in Chile and Argentina, global travelers, and researchers fighting rare infectious diseases.

The Silent Threat: A Deadly Global Family

A rare but deadly rodent-borne hantavirus outbreak on a cruise ship has exposed the global lack of approved treatments. While not a novel pathogen, hantaviruses have existed for decades without a universally approved vaccine.

The virus typically spreads when people inhale contaminated residue of rodent droppings. However, the Andes virus variant, which triggered the cruise outbreak, is uniquely capable of spreading between humans in close contact.

While infections are rare, they are highly lethal. The Ministry of Health in Chile reported 15 deaths out of 42 cases this year, while Argentina has seen 32 deaths out of 102 cases since June 2025.

New Hope: Repurposing Existing Drugs

Argentinian researchers are investigating whether tocilizumab, a rheumatoid arthritis drug, can combat hantavirus pulmonary syndrome. The drug works by tamping down the inflammatory molecule IL-6 to prevent lungs from filling with fluid.

A study published in The Lancet Infectious Diseases revealed that four out of five hospital patients survived after receiving tocilizumab. Conversely, five eligible patients who did not receive the drug died.

"I hope this situation will help us continue our research and strengthen the collaboration between healthcare workers, the community, and the necessary resources," said Dr. Fernando Tortosa, the study's lead author.

Antibody Therapies and Vaccine Development

Scientists are also testing cloned antibodies from survivors. A Chilean-led team successfully proved this approach in animals back in 2018, but funding was diverted to fight the coronavirus pandemic before human trials could begin.

On the vaccine front, a team led by Jay Hooper of the U.S. Army Medical Research Institute of Infectious Diseases has shown promise. Their candidate successfully generated antibodies in early-stage human trials.

• Tocilizumab therapy: Targets inflammation and lung fluid buildup in severe cases.
• Cloned antibodies: Uses survivor immunity to neutralize infections, pending human trial funding.
• DNA vaccines: Early-stage candidates show successful antibody generation against the Andes virus.

Why Finding Support Remains a Challenge

Despite clinical promise, researchers face a steep uphill battle. Pharmaceutical companies and governments are reluctant to fund extensive safety trials due to the sporadic nature of outbreaks.

Stanford Medical Center researcher Dr. Paul Bollyky explains that laboratories lack the machinery to validate rare disease treatments. Conducting clinical trials is extremely difficult and impractical because predicting who will be exposed is nearly impossible.

What to Watch Next

Researchers will monitor whether the cruise ship outbreak spurs new investments from global health organizations and pharmaceutical companies. Future studies will also focus on expanding clinical trials for tocilizumab and cloned antibody therapies. Additionally, scientists hope to advance vaccine candidates to larger-scale human testing before the next seasonal spike.